mail
versión imprimible
 
 

10th Neurodegenerative Drug Development Summit

Evvnt Promotion / evvnt
Archivo
-
28.03.2022 - 30.03.2022  Boston Park Plaza, 50 Park Plaza, 02116 Boston, USA
Time: 8:00 AM - 3:30 PM
 
Temas de la conferencia
With Biogen’s Aducanumab approval dramatically overhauling the regulatory landscape for neurodegenerative disease, the beta amyloid revival is in full swing with investment pouring in across multiple neurodegenerative diseases. With this, biopharma across the globe are racing to harness the exhilarating momentum of the past year and turbocharge their neurodegenerative disease drug development in 2022 and beyond.
Organizador profesional (PCO)
Hanson Wade
 

Información e inscripción:

https://go.evvnt.com/961759-2?pid=4832
Ms. Stephanie Nketia
 
Categorías
Investigación clínica, Medicina General
Idioma
Inglés
Cuota del Congreso
USD 2399.00 - USD 4598.00
Cantacto organizador
83 Great Titchfield Street
W1W 6RH London
United Kingdom
 
"Going International fomenta el acceso a la educación y a la formación continua independientemente de fronteras sociales, geográficas y nacionales."

AGEM - Arbeitsgemeinschaft Ethnologie und MedizinAnästhesie in Entwicklungsländern e. V.Helix - Forschung & Beratung WienOÖ Gebietskrankenkasse, Referat für Wissenschaftskooperation Swiss Tropical and Public Health InstituteEuropean Health Forum GasteinÖsterreichische Gesellschaft für Public HealthÄrztekammer für Wien